Concurrent duodenal manometric and impedance recording to evaluate the effects of hyoscine on motility and flow events, glucose absorption, and incretin release.
Upper gastrointestinal motor function and incretin hormone secretion are major determinants of postprandial glycemia and insulinemia. However, the impact of small intestinal flow events on glucose absorption and incretin release is poorly defined. Intraluminal impedance monitoring is a novel technique that allows flow events to be quantified. Eight healthy volunteers were studied twice, in random order. A catheter incorporating six pairs of electrodes at 3-cm intervals, and six corresponding manometry sideholes, was positioned in the duodenum. Hyoscine butylbromide (20 mg) or saline was given as an intravenous bolus, followed by a continuous intravenous infusion of either hyoscine (20 mg/h) or saline over 60 min. Concurrently, glucose and 3-O-methylglucose (3-OMG) were infused into the proximal duodenum (3 kcal/min), with frequent blood sampling to measure glucose, 3-OMG, insulin, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). The frequency of duodenal pressure waves and propagated pressure wave sequences was reduced by hyoscine in the first 10 min (P<0.01 for both), but not after that time. In contrast, there were markedly fewer duodenal flow events throughout 60 min with hyoscine (P<0.005). Overall, blood glucose (P<0.01) and plasma 3-OMG concentrations (P<0.05) were lower during hyoscine than saline, whereas plasma insulin, GLP-1, and GIP concentrations were initially (t=20 min) lower during hyoscine (P<0.05). In conclusion, intraluminal impedance measurement may be more sensitive than manometry in demonstrating alterations in duodenal motor function. A reduction in the frequency of duodenal flow events is associated with a decreased rate of glucose absorption and incretin release in healthy subjects.
Chaikomin
Reawika
R
Discipline of Medicine, Royal Adelaide Hospital, North Terrace, Adelaide, SA, Australia.
Wu
Keng Liang
KL
Doran
Selena
S
Jones
Karen L
KL
Smout
Andre J P M
AJ
Renooij
Willem
W
Holloway
Richard H
RH
Meyer
James H
JH
Horowitz
Michael
M
Rayner
Christopher K
CK
D019325:3-O-Methylglucose / Q000097:blood / Q000378:metabolism; D000328:Adult; D001786:Blood Glucose / Q000187:drug effects; D002086:Butylscopolammonium Bromide / Q000494:pharmacology*; D016022:Case-Control Studies; D004386:Duodenum / Q000187:drug effects* / Q000294:innervation / Q000378:metabolism; D017097:Electric Impedance; D005749:Gastric Inhibitory Polypeptide; D005769:Gastrointestinal Motility / Q000187:drug effects*; D005772:Gastrointestinal Transit / Q000187:drug effects; D052216:Glucagon-Like Peptide 1 / Q000097:blood*; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D007328:Insulin / Q000097:blood; D007408:Intestinal Absorption / Q000187:drug effects*; D008297:Male; D008365:Manometry / Q000379:methods; D018727:Muscarinic Antagonists / Q000494:pharmacology*; D010528:Peristalsis / Q000187:drug effects; D012016:Reference Values; D012680:Sensitivity and Specificity; D016037:Single-Blind Method; D013997:Time Factors
D001786:Blood Glucose; D007328:Insulin; D018727:Muscarinic Antagonists; D019325:3-O-Methylglucose; D002086:Butylscopolammonium Bromide; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D005947:Glucose